ANGLE PLC ORD - ANPCF STOCK NEWS

ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.

ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.

The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with NuProbe USA, Inc. for the use of their proprietary pan-cancer next generation sequencing (NGS) panel. The agreement grants ANGLE an option for an exclusive global license to the NGS panel outside of China for analyzing circulating tumor cells (CTCs) and dual analysis of CTCs and circulating tumor DNA (ctDNA).

The NGS panel enables highly sensitive detection of over 6,500 DNA mutations in 61 clinically relevant genes. It has been validated on the Illumina sequencer and aligns with key drug targets under development by large pharma. This agreement aims to accelerate ANGLE's commercialization of its first pan-cancer molecular sequencing assay, with immediate applicability to pharma services customers and translational researchers using the Parsortix® system.

A pilot study conducted by ANGLE demonstrated that more mutations were identified exclusively in CTCs compared to ctDNA alone in breast, lung, and ovarian cancer patients, highlighting the potential value of profiling CTCs in addition to ctDNA.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.

An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.

ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.

On July 12, 2024, Angle PLC, a UK-based company, announced a significant change in its major shareholdings. Dermot Keane, based in London, UK, has crossed the 5% threshold, increasing his voting rights from 4.90% to 8.09%, amounting to 26,110,422 voting rights. The notification was triggered by an acquisition of voting rights, with the official threshold crossing occurring on June 5, 2024. This information was published through the London Stock Exchange's Regulatory News Service (RNS), approved by the Financial Conduct Authority (FCA). No other financial instruments or changes in voting rights breakdown were reported.

ANGLE plc, a leader in liquid biopsy solutions for CTCs, announced the posting of its 2023 Annual Report and Financial Statements. The report, covering the year ending December 31, 2023, is available on the company's website. Shareholders have been invited to the Annual General Meeting (AGM) scheduled for July 11, 2024, at the Surrey Technology Centre. The AGM will include a business update following formal proceedings. This announcement is significant for stakeholders tracking corporate governance and financial performance of ANGLE plc.

ANGLE announces the showcasing of its Parsortix system and assays at the European Association for Cancer Research (EACR) 2024 Annual Congress.

The company highlights two key presentations: the dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for genetic profiling in ovarian, breast, and lung cancer patients, and the use of its DNA Damage Response (DDR) assay to monitor treatment effectiveness in ovarian and prostate cancer patients.

The presentations demonstrate the Parsortix system's potential for personalized cancer treatment and therapeutic monitoring.